NASDAQ:OXFD - Oxford Immunotec Global Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$13.87 -0.21 (-1.49 %)
(As of 06/22/2018 04:00 PM ET)
Previous Close$13.87
Today's Range$13.68 - $14.26
52-Week Range$10.00 - $19.51
Volume434,580 shs
Average Volume164,007 shs
Market Capitalization$364.41 million
P/E RatioN/A
Dividend YieldN/A
Oxford Immunotec Global logoOxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. The company develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions. It develops and markets T-SPOT.TB test used to test for tuberculosis. The company is also developing a range of assays for tick-borne diseases, such as lyme disease, as well as for use in screening blood for the parasite babesia microti that causes babesiosis; and T-SPOT.CMV test that measures the strength of a patient's cellular response to CMV infection. Oxford Immunotec Global PLC markets its T-SPOT.TB test through a direct sales force in the United States, certain European countries, and Japan, as well as through distributors in other parts of the world. Oxford Immunotec Global PLC was founded in 2002 and is headquartered in Abingdon, the United Kingdom.

Receive OXFD News and Ratings via Email

Sign-up to receive the latest news and ratings for OXFD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Diagnostic substances


Debt-to-Equity Ratio0.38
Current Ratio5.60
Quick Ratio5.04


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$103.08 million
Price / Sales3.48
Cash FlowN/A
Price / CashN/A
Book Value$3.42 per share
Price / Book4.06


EPS (Most Recent Fiscal Year)($1.36)
Net Income$-32,880,000.00
Net Margins-34.13%
Return on Equity-43.51%
Return on Assets-24.49%


Outstanding Shares25,880,000

Oxford Immunotec Global (NASDAQ:OXFD) Frequently Asked Questions

What is Oxford Immunotec Global's stock symbol?

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

How were Oxford Immunotec Global's earnings last quarter?

Oxford Immunotec Global PLC (NASDAQ:OXFD) announced its quarterly earnings results on Tuesday, May, 1st. The company reported ($0.40) EPS for the quarter, topping analysts' consensus estimates of ($0.45) by $0.05. The company earned $21.37 million during the quarter, compared to analyst estimates of $20.96 million. Oxford Immunotec Global had a negative return on equity of 43.51% and a negative net margin of 34.13%. The firm's revenue was down .7% on a year-over-year basis. During the same quarter last year, the firm posted ($0.36) earnings per share. View Oxford Immunotec Global's Earnings History.

When is Oxford Immunotec Global's next earnings date?

Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Tuesday, August, 7th 2018. View Earnings Estimates for Oxford Immunotec Global.

What price target have analysts set for OXFD?

4 Wall Street analysts have issued 1 year price targets for Oxford Immunotec Global's stock. Their predictions range from $15.00 to $20.00. On average, they expect Oxford Immunotec Global's stock price to reach $18.25 in the next year. View Analyst Ratings for Oxford Immunotec Global.

Who are some of Oxford Immunotec Global's key competitors?

Who are Oxford Immunotec Global's key executives?

Oxford Immunotec Global's management team includes the folowing people:
  • Dr. Peter Wrighton-Smith, CEO & Exec. Director (Age 44)
  • Mr. Richard M. Altieri, CFO and Principal Financial & Accounting Officer (Age 58)
  • Mr. Jeff R. Schroeder, Pres, Strategic Accounts (Age 57)
  • Mr. Stefan C. Linn, Chief Operating Officer (Age 53)
  • Ms. Karen C. Koski, Head of Strategy & Investor Relations

Has Oxford Immunotec Global been receiving favorable news coverage?

Media stories about OXFD stock have been trending positive recently, according to Accern. The research group scores the sentiment of media coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oxford Immunotec Global earned a media sentiment score of 0.26 on Accern's scale. They also assigned press coverage about the company an impact score of 45.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are Oxford Immunotec Global's major shareholders?

Oxford Immunotec Global's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (9.54%), BlackRock Inc. (4.49%), Wasatch Advisors Inc. (2.88%), First Light Asset Management LLC (2.42%), Cortina Asset Management LLC (1.98%) and Northern Trust Corp (1.00%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Jeff R Schroeder, Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.

Which institutional investors are selling Oxford Immunotec Global stock?

OXFD stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Cortina Asset Management LLC, Tiverton Asset Management LLC, Millennium Management LLC, Neuburgh Advisers LLC, Flinton Capital Management LLC, C WorldWide Group Holding A S and Northern Trust Corp. Company insiders that have sold Oxford Immunotec Global company stock in the last year include Peter Edwardson, Peter Wrighton-Smith and Richard A Sandberg. View Insider Buying and Selling for Oxford Immunotec Global.

Which institutional investors are buying Oxford Immunotec Global stock?

OXFD stock was acquired by a variety of institutional investors in the last quarter, including Wasatch Advisors Inc., Redmile Group LLC, BlackRock Inc., Spark Investment Management LLC, Birchview Capital LP, First Light Asset Management LLC, Trexquant Investment LP and Kornitzer Capital Management Inc. KS. View Insider Buying and Selling for Oxford Immunotec Global.

How do I buy shares of Oxford Immunotec Global?

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oxford Immunotec Global's stock price today?

One share of OXFD stock can currently be purchased for approximately $13.87.

How big of a company is Oxford Immunotec Global?

Oxford Immunotec Global has a market capitalization of $364.41 million and generates $103.08 million in revenue each year. The company earns $-32,880,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. Oxford Immunotec Global employs 457 workers across the globe.

How can I contact Oxford Immunotec Global?

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]

MarketBeat Community Rating for Oxford Immunotec Global (OXFD)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  146 (Vote Outperform)
Underperform Votes:  128 (Vote Underperform)
Total Votes:  274
MarketBeat's community ratings are surveys of what our community members think about Oxford Immunotec Global and other stocks. Vote "Outperform" if you believe OXFD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OXFD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/23/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.